vivimusta Drug Patent Profile
✉ Email this page to a colleague
When do Vivimusta patents expire, and what generic alternatives are available?
Vivimusta is a drug marketed by Slayback Pharma Llc and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in VIVIMUSTA is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vivimusta
A generic version of vivimusta was approved as bendamustine hydrochloride by ACCORD HLTHCARE on December 7th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for vivimusta?
- What are the global sales for vivimusta?
- What is Average Wholesale Price for vivimusta?
Summary for vivimusta
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 130 |
Patent Applications: | 1,933 |
Drug Prices: | Drug price information for vivimusta |
What excipients (inactive ingredients) are in vivimusta? | vivimusta excipients list |
DailyMed Link: | vivimusta at DailyMed |
![vivimusta drug patent expirations Drug patent expirations by year for vivimusta](/p/graph/s/t/vivimusta-patent-expirations.png)
![Drug Prices for vivimusta](/p/graph/drug-price/vivimusta.png)
Pharmacology for vivimusta
Drug Class | Alkylating Drug |
Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for vivimusta
vivimusta is protected by one US patents.
Patents protecting vivimusta
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Slayback Pharma Llc | VIVIMUSTA | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 212209-001 | Dec 7, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |